1KPA.F PROTARA THERAPEUT.DL-001

Healthcare Biotechnology Frankfurt Exchange
2.35 EUR
Close of Nov 11, 2026
1.72 6.50
Market cap
EUR 145M
P/E
-
P/B
1.02x
ROE
-57.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1KPA.F undervalued?

Graham number

The Graham number of PROTARA THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PROTARA THERAPEUT.DL-001 fundamental analysis

No fundamental analysis for PROTARA THERAPEUT.DL-001 yet.

PROTARA THERAPEUT.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PROTARA THERAPEUT.DL-001

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for pa…

Full company profile